Financetoday
financialTelegram

Lawmakers Press HHS on Betting Markets Tied to Drug Trials

Regulation·November 12, 2026

Two senators want the Department of Health and Human Services to explain how it is handling a growing category of online betting products. Sens. Angela Alsobrooks and Ron Wyden have asked HHS what steps it has taken to reduce the risks posed by prediction markets that let users wager on the outcomes of clinical trials and drug approval decisions.

Prediction markets let people buy and sell contracts that pay out depending on whether a future event happens. When that event is a drug succeeding in a trial or a regulator approving a treatment, the stakes move quickly into public health territory. Anyone with early access to trial results or review timelines could profit from information the public does not have, and the prices in these markets could give a distorted picture of a company's prospects.

The senators' inquiry centers on safeguards. Lawmakers want to know what protections the department has considered or put in place to keep these markets from being used in ways that harm patients, investors, or the integrity of the approval process.

The letter also feeds a wider debate over whether contracts tied to medical outcomes belong on regulated platforms at all. Supporters argue that such markets can pool dispersed information and produce useful forecasts. Critics respond that when the underlying event is a medical result that a small group of insiders may see first, the incentives are hard to justify.

The source material does not say how or when HHS plans to respond to the senators, so the department's position remains unclear for now.

Reporting based on an external source.